Trastuzumab combined with doublet or single-agent chemotherapy as first-line therapy for HER2-positive metastatic breast cancer

PURPOSE: To investigate the efficacy and safety of doublet versus single-agent chemotherapy (CT) plus trastuzumab (H) as first-line therapy for human epidermal growth factor 2 receptor (HER2)-positive metastatic breast cancer (MBC). METHODS: We searched for randomized clinical trials (RCTs) that eva...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Breast Cancer Res Treat
Huvudupphovsmän: Yu, Y. F., Wang, Y., Fu, T. P., Chen, K., Liu, J. Q., Yao, H. R.
Materialtyp: Artigo
Språk:Inglês
Publicerad: Springer US 2017
Ämnen:
Clinical Trial
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC5838135/
https://ncbi.nlm.nih.gov/pubmed/29188398
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-017-4592-y
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk